ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 882

Lung Damage in ANCA Associated Vasculitis Assessed By Vasculitis Damage Index: Recurrent Pulmonary Infections Have a Significant Contribution

Esra Aydın1, Bahtiyar Toz2, Burak Erer3, Nilufer Alpay Kanitez2, Mustafa Erelel4, Ahmet Gocmez5, Ahmet Gul3, Murat Inanc3, Lale Ocal3 and Sevil Kamali3, 1Department of Internal Medicine,, istanbul faculty of medicine, istanbul, Turkey, 2Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 3Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 4Department of Pulmonology, Istanbul University Istanbul Faculty of Medicine Department of Pulmonology, istanbul, Turkey, 5Department of Radiology, Istanbul University Istanbul Faculty of Medicine, istanbul, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Lung and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Vasculitis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Vasculitis damage index (VDI) is a validated comprehensive damage tool which has been developed as an outcome measure and consists of different types of lung damage items. We aimed to investigate lung damage in AAV by using VDI.

Methods: We analysed 51 patients (25 female) with AAV (40 GPA, 8 MPA, 3 e-GPA) and lung involvement who met ACR criteria and followed-up from a single tertiary center, between 1998-2014. Demographic and clinical features, smoking and exposure history, severe infections (SI) requiring hospitalization, relapse rates and immunsuppressive doses were recorded. Initial BVAS scores and imaging findings were noted. Severe pulmonary infections requiring hospitalization were recorded. Pulmonary function tests (PFT), 6MWT, HRCT and VDI scores were obtained. Correlation analysis was performed for BVAS and VDI scores. VDI scores were compared between the groups stratified in accordance to the presence and recurrence of severe pulmonary infections by Mann-Whitney U test.

Results: Lung involvement was investigated by imaging (X-Ray/HRCT) (100%), histopathology (15%) or bronchoscopy (25%). ANCA positivity was found in 94% (66% C-ANCA/anti-PR3, 34% p-ANCA/anti-MPO). Mean age at diagnosis, time between the first symptom and diagnosis and total follow-up time were 49±13 y (med 51), 4,8±5,8 mo,(med 3) and 66,5±52 mo (med 47), respectively. 28 patients were smokers. Kidney was the most frequently involved organ (78%) with lung. Initial total and lung BVAS were 22±7 (4-38) (med 23) and 4,6±2,8, respectively.The frequency of BVAS items were as follows: Nodules/cavities 80%, infiltration 52%, massive haemoptysis/alveolar haemorrhage 19%, respiratory failure 11%, pleural effusion/pleurisy 5%, endobronchial involvement 3 %. Respiratory failure developed in 11% at presentation. Cumulative total and lung VDI scores were 3,4±2,2 (0-9) (med 3), 0.4±0.8 (0-4) (med 1) respectively. The frequency of VDI lung items were 21% for impaired lung function, 7% for pulmonary fibrosis, 5% for chronic breathlesness, 1% for pulmonary hypertension. AAV patients had 1 (24%), 2 (12%) or 4 (1%) items of VDI. VDI scores of lung items in AAV subgroups were shown in Table-1. One of four patients who suffered from respiratory failure died. Severe pulmonary infections (>1 SI in 33%) were detected in 44%. VDI was higher in patients who suffered from pulmonary infection but, it was statistically insignificant (4.1±.4 vs 3±1.9, p>0.05). The patients with recurrent severe pulmonary infections had significantly high VDI scores when compared to the patients with only one infection (4.8±2.7 vs 3±1.9, p= 0.02). No significant correlation was found between BVAS and VDI scores.

 

 VDI items

GPA

n (%)

MPA

n (%)

e-GPA

n (%)

Pulmonary Hypertension

–

–

1 (2)

Pulmonary Fibrosis

1 (2)

3 (6)

–

Pulmonary Infarct

–

–

–

Pleural Fibrosis

–

–

–

Chronic Asthma

–

–

2 (4)

Chronic Breathlesness

2 (4)

– 

1 (2)

Impaired Lung Function

5 (10)

3 (6)

3 (6)

Conclusion: VDI is a useful tool to demonstrate lung damage in AAV. Lung damage has been demonstrated in almost 40% of AAV patients. Recurrent pulmonary infections seem to be an important contributor to the lung damage in AAV.


Disclosure: E. Aydın, None; B. Toz, None; B. Erer, None; N. Alpay Kanitez, None; M. Erelel, None; A. Gocmez, None; A. Gul, None; M. Inanc, None; L. Ocal, None; S. Kamali, None.

To cite this abstract in AMA style:

Aydın E, Toz B, Erer B, Alpay Kanitez N, Erelel M, Gocmez A, Gul A, Inanc M, Ocal L, Kamali S. Lung Damage in ANCA Associated Vasculitis Assessed By Vasculitis Damage Index: Recurrent Pulmonary Infections Have a Significant Contribution [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/lung-damage-in-anca-associated-vasculitis-assessed-by-vasculitis-damage-index-recurrent-pulmonary-infections-have-a-significant-contribution/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lung-damage-in-anca-associated-vasculitis-assessed-by-vasculitis-damage-index-recurrent-pulmonary-infections-have-a-significant-contribution/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology